Turning Point and Libtayo steal some pre-Asco thunder
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
The patent winter is coming
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
Alnylam shoots for the heart
With readout of Apollo-B approaching, can Onpattro succeed where Bridgebio’s acoramidis failed?
Late-stage pain pipeline refuses to swell
Setbacks from Eliem, Ampio and Acadia thin an already sparse pain pipeline, which remains lacking in serious interest from big developers.
